YZY Biopharma was founded in July 2010 to develop bi-specific antibodies against a broad range of cancers.In January 2018, the company CSPC NBP Pharmaceutical, a wholly-owned subsidiary of CSPC Pharmaceuticals Group Limited, entered into an equity transfer and capital increase agreement to acquire Wuhan YZY at an aggregate of 39.56% through the acquisiton and captial injection at a total consideration of RMB 356,000,000. The equity transfer agreement would be with the vendors and the other existing shareholders of Wuhan YZY agreed for 37% equity interest at a total consideration of RMB203,574,000. At that time, the acquistion was expected to close within 20 days after the date of the equity transfer agreement. The capital increase agreement had RMB76,242,000 inject to Wuhan YZY. Also the company CSPC NBP agreed for additional milestone amounts aggregating up to RMB 20,758,000 to the capital reserve of Wuhan YZY and also further agreed to inject additional milestone amounts aggregating up to RMB22,042,000,